Boardroom Alpha
Boardroom Alpha
LWAY · Current Report (Form 8-K) · Filed December 31, 2025

Lifeway Foods Inc — Current Report (Form 8-K)

Form
8-K
Filed
December 31, 2025
Period
Dec 29, 2025
Ticker
LWAY
Accession
0001683168-25-009435
Boardroom Alpha · Filing insights

Shareholders re-elected the board slate, rejected governance amendments and committee proposal, ratified auditors, and approved an annual executive pay vote.

About Lifeway Foods Inc
Market cap
$345M
1Y TSR
+3.3%
3Y TSR
+55.8%
Board grade
C
Sector
Consumer Defensive
CEO
Julie Smolyansky
Last annual meeting: Jun 17, 2026 · View full Lifeway Foods Inc profile →
LIFEWAY FOODS, INC. 8-K

`

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 29, 2025

 

LIFEWAY FOODS, INC.

(Exact name of registrant as specified in its charter)

 

ILLINOIS   000-17363   36-3442829

(State or other jurisdiction of

incorporation)

  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

6431 Oakton St. Morton Grove, IL   60053
(Address of principal executive offices)   (Zip code)

 

Registrant’s telephone number, including area code: (847) 967-1010

 

          N/A          

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class Trading Symbol Name of each exchange on which registered
Common Stock, no par value LWAY The Nasdaq Stock Market
Preferred Stock Purchase Rights None The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b 2 of this chapter). Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

   

 

 

Item 5.07.    Submission of Matters to a Vote of Security Holders.

 

The 2025 Annual Meeting of Shareholders (the “Annual Meeting”) of Lifeway Foods, Inc. (the “Company”) was held on December 29, 2025. There were 15,228,763 shares of common stock outstanding and entitled to vote at the Annual Meeting and 12,441,533 shares of common stock were represented in person or by proxy at the Annual Meeting, constituting a quorum. First Coast Results, Inc., the independent inspector of elections for the 2025 Annual Meeting, provided a final voting report on December 30, 2025, certifying the following results.

 

Proposal 1:

 

According to the tabulation of voting results, the following is a record of votes cast with respect to the election of Kirk Chartier, Juan Carlos Dalto, Rachel Drori, Andee Harris, Susie Hultquist, Dorri McWhorter, Jason Scher and Julie Smolyansky, to serve until the 2026 Annual Meeting of the Company’s shareholders (or until successors are elected and qualified):

 

  FOR WITHHOLD BROKER NON-VOTES
Board of Directors’ Nominees      
Kirk Chartier 8,947,067 3,442,164 0
Juan Carlos Dalto 8,862,987 3,526,244 0
Rachel Drori 8,947,911 3,441,319 0
Andee Harris 8,947,751 3,441,480 0
Susie Hultquist 8,947,871 3,441,360 0
Dorri McWhorter 8,588,825 3,800,405 0
Jason Scher 8,582,061 3,807,170 0
Julie Smolyansky 8,836,589 3,552,642 0
       
Opposition Nominees      
George Sent 3,435,783 8,983,447 0
Edward Smolyansky 3,435,344 8,953,886 0

  

 

 

 

 

 2 

 

 

Proposal 2:

 

According to the tabulation of voting results, the shareholders did not approve and adopt amendments to the Company’s Articles of Incorporation to provide for:

 

(a) the amendment and restatement of the Company’s Articles of Incorporation to effectuate ministerial changes and to provide for director exculpation

 

FOR: 8,700,709
AGAINST: 123,072
ABSTAIN: 3,593,949
BROKER NON-VOTES: 23,803

 

(b) director indemnification and expense advancement

 

FOR: 8,696,518
AGAINST: 131,248
ABSTAIN: 3,590,140
BROKER NON-VOTES: 23,803

 

Proposal 3:

 

According to the tabulation of voting results, the shareholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accountants for the year ending December 31, 2025:

 

FOR: 9,021,417
AGAINST: 69,580
ABSTAIN: 3,350,536
BROKER NON-VOTES: 0

 

 

 

 

 3 

 

 

Proposal 4:

 

According to the tabulation of voting results, the shareholders approved, on a nonbinding advisory basis, executive compensation.

 

FOR: 6,590,702
AGAINST: 5,781,223
ABSTAIN: 45,805
BROKER NON-VOTES: 23,803

 

Proposal 5:

 

According to the tabulation of voting results, the shareholders selected, on a non-binding advisory basis, a 1 year frequency of holding the say-on-executive compensation vote.

 

1 YEAR: 12,221,140
2 YEARS: 45,021
3 YEARS: 114,710
ABSTAIN: 36,589

 

Proposal 6:

 

According to the tabulation of voting results, the shareholders did not approve the shareholder proposal to form a committee of the board to conduct reviews of the Company’s management, the Company’s strategic plan and the Company’s strategic alternatives.

 

FOR: 3,619,138
AGAINST: 8,520,935
ABSTAIN: 277,657
BROKER NON-VOTES: 23,803

 

In accordance with the expressed preference of our shareholders reflected in the nonbinding advisory vote for Proposal 5 and the recommendation of the Board, the Board have determined that we will include a nonbinding advisory shareholder vote on executive compensation of our named executive officers in our proxy materials on an annual basis until the next required advisory vote on the frequency of shareholder votes on executive compensation, which will occur no later than our annual meeting of stockholders in 2031.

 

 

 4 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

LIFEWAY FOODS, INC.

 

 

 
Dated: December 30, 2025 By: /s/ Julie Smolyansky  
    Name: Julie Smolyansky  
    Title: Chief Executive Officer and Secretary  

 

 

 

 

 

 

 

 

 5 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Lifeway Foods Inc (LWAY)

Reference

Frequently asked questions

When did Lifeway Foods Inc file this 8-K?
Lifeway Foods Inc (LWAY) filed this Current Report (Form 8-K) with the SEC on December 31, 2025. The accession number assigned by EDGAR is 0001683168-25-009435.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Shareholders re-elected the board slate, rejected governance amendments and committee proposal, ratified auditors, and approved an annual executive pay vote. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Lifeway Foods Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Lifeway Foods Inc has filed under CIK 814586, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer